GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » Marketable Securities

XTL Biopharmaceuticals (XTAE:XTLB) Marketable Securities : ₪2.79 Mil (As of Dec. 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. XTL Biopharmaceuticals's Marketable Securities for the quarter that ended in Dec. 2024 was ₪2.79 Mil.

XTL Biopharmaceuticals's annual Marketable Securities declined from Dec. 2022 (₪5.88 Mil) to Dec. 2023 (₪2.19 Mil) but then increased from Dec. 2023 (₪2.19 Mil) to Dec. 2024 (₪2.79 Mil).

XTL Biopharmaceuticals Marketable Securities Historical Data

The historical data trend for XTL Biopharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals Marketable Securities Chart

XTL Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.71 11.40 5.88 2.19 2.79

XTL Biopharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.19 4.59 3.58 3.25 2.79

XTL Biopharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

XTL Biopharmaceuticals  (XTAE:XTLB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

XTL Biopharmaceuticals Marketable Securities Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

XTL Biopharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » Marketable Securities
Comparable Companies
XTAE:EVGN XTAE:CBI XTAE:BOLT XTAE:BLRX XTAE:MTLF XTAE:CANF XTAE:PPBT XTAE:PLNT XTAE:HDST-M XTAE:KDST VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
XTLB:USA H2K2:Germany
Address
26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
Website
https://www.xtlbio.com
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.